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Oral Presentations 23marked for CLL, mantle cell lymphoma and Hodgkin’s lymphoma.
Our results suggest that including sirolimus in the GVHD prophy-
laxis regimen during SCT is beneficial for patients with lymphoma,
and opens the way for clinical trials assessing its optimal use in this
patient population.55
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Background:CD70 is a tumor necrosis family member that is ex-
pressed on a broad spectrum of hematological malignancies includ-
ing multiple myeloma, non-Hodgkin’s lymphomas and Hodgkin’s
disease. In contrast to other immunotherapy targets such as
CD19, CD20, or CD33, which are widely expressed in the hemato-
poietic system, CD70 expression is restricted to a subset of activated
B and T cells, reducing potential ‘collateral damage’ when targeted
by immunotherapy. Preclinical studies in animal models using
monoclonal antibodies have validated CD70 as an immunothera-
peutic target and the aim of this study was to generate CD70-spe-
cific T cells for adoptive immunotherapy approaches. Methods &
Results: To create CD70-specific T cells we constructed
a CD70-specific chimeric antigen receptor (CD70-CAR) consisting
of domains derived from the CD70 receptor (CD27) and the T-cell
receptor CD3-z chain. CD70-specific T cells were generated by
transducing CD3/CD28-activated T cells with a SFG retroviral
vector encoding the CD70-CAR construct and cell surface expres-
sion was confirmed by FACS analysis. CD70-specific T cells from
healthy donors proliferated and produced IFN-g as well as IL-2
in contrast to mock transduced T cells after coculture with
CD70-positive myeloma cells (U266 and ARH-77) and lympho-
blastoid cell lines. In cytotoxicity assays, CD70-specific T cells
killed CD70-positive myeloma cell lines and lymphoblastoid cell
lines where as activated lymphocytes that express CD70 at low levels
and CD70-negatvie targets were not killed. Conclusion: We have
successfully constructed a CD70-CAR and demonstrate that
CD70-specific T cells selectively recognize and kill malignant cells
that express CD70 high levels. Murine xenograft studies are in
progress to confirm these findings in vivo. Adoptive immunother-
apy with CD70-specific T cells may represent a promising immuno-
therapeutic approach for CD70-positive hematological
malignancies.56
VACCINATION WITH DC/MM FUSIONS IN CONJUNCTION WITH STEM
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Autologous transplantation results in the transient reversal of tu-
mor mediated tolerance due to the reduction in disease bulk, the de-
pletion of regulatory T cells, and the increase in tumor reactive
lymphocytes during the period of lymphopoietic reconstitution.
As a result, cancer vaccines are being explored as a means of target-
ing residual myeloma cells following transplant. We developed
a cancer vaccine in which patient derived tumor cells are fused
with autologous dendritic cells (DCs). We are conducting a study
in which patients with multiple myeloma (MM) undergo stem cell
transplant followed by vaccination with DC/MM fusions. DCs
were generated from adherent mononuclear cells cultured with
GM-CSF and IL-4 for 5–7 days and matured with TNFa. MM cells
were isolated from bone marrow aspirates and were identified by
their expression of CD38, CD138, and/or MUC1. DC and MMcells were fused with polyethylene glycol. Fusion cells were quanti-
fied by determining the percentage of cells that coexpress unique
DC and MM antigens. To date, 19 patients have been enrolled
and 18 have completed vaccine generation. Mean yield of the DC
and MM cells was 1.84  108 and 8.3  107 cells, respectively.
Mean fusion efficiency was 40% and the mean dose of fusion cells
generated was 4.3  106. As a measure of their immunologic po-
tency, fusion cells prominently stimulated allogeneic T cell prolif-
eration in vitro. Mean stimulation indexes were 12, 57, and 31 for
T cells stimulated by MM cells, DCs, and fusion cells, respectively.
6 patients have completed follow up and 3 are undergoing vaccina-
tion. 3 patients demonstrated resolution of post-transplant parapro-
tein following vaccination. 1 patient with disease progression early
post-transplant demonstrated initial response then disease stabiliza-
tion with vaccination. We are examining the effect of vaccination on
measures of anti-tumor immunity and levels of activated as com-
pared to regulatory T cells. In preliminary studies, an increase in
the ratio of activated (CD4/CD25low) to regulatory (CD4/
CD25high) T cells was observed. To date, all evaluable patients dem-
onstrated evidence of vaccine stimulated anti-tumor immunity as
manifested by a rise in IFNg expression by CD4 and/or CD81 T
cells in response to ex vivo exposure to autologous tumor lysate.
In this ongoing study, fusion cell vaccination followjng stem cell
transplant has been well tolerated, induced anti-tumor immunity
and clinical responses in patients with MM.PEDIATRIC DISORDERS57
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Minimal residual disease (MRD) quantified prior to allogeneic
stem cell transplantation (SCT) has been shown to predict outcome
in children with relapsed acute lymphoblastic leukemia (ALL) in
retrospective meta analysis. Within the ALL-REZ BFM Group
we have started a prospective trial evaluating the impact of pre-
transplant MRD load in a well defined group of children who re-
ceived their transplant in second or subsequent remission.
Patients: Between March 1999 and July 2005, 91 children with
relapsed ALL treated according to the protocols ALL-REZ BFM
96 or 2002 and receiving allogeneic SCT in 2nd (n 5 77) or 3rd
CR (n 5 14) have been enrolled. MRD quantification was per-
formed within 40 days prior to SCT by real time PCR using T-
cell receptor and immunoglobulin gene rearrangements as clone-
specific targets with at least 1 marker with a sensitivity of 10–4.
Results: Probability of event free survival (pEFS) in 45 patients
with MRD $10–4 was 0.27 (60.07) compared with 0.60 (60.08)
in 46 patients with MRD\10–4 (p 5 0.036). Clinical and thera-
peutical parameters were equally distributed between both sub-
groups. The difference in pEFS was more prominent in
intermediate risk patients (S2, n 5 35, 0.20 (60.12) versus 0.68
(60.12), (p 5 0.02)) than in high risk patients (S3/S4/CR3, n 5
56, 0.30 (60.09) versus 0.50 (60.11), (p 5 0.006)). Multivariate
Cox regression analysis revealed MRD as the only independent pa-
rameter predictive for EFS (p5 0.006).Conclusion:MRD prior to
allogeneic SCT proves to be the most important risk factor for out-
come post transplantation. Early prediction of MRD response until
SCT is necessary to allow timely experimental interventions in pa-
tients with persistent high level MRD. New strategies with modified
SCT procedures including conditioning regimen, graft manipula-
tion, and GVHD prophylaxis and/or post transplant intervention
strategies should be evaluated to improve the antileukemic efficacy
post SCT in patients with a high probability of subsequent relapse.
